Maureen M. Hattersley

AstraZeneca (South Korea) — South Korea

Biochemistry, Genetics and Molecular Biology · Life Sciences

22h-index1.7kcitations130works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(51), Adenosine and Purinergic Signaling(28), Pharmacological Receptor Mechanisms and Effects(24), Multiple Myeloma Research and Treatments(23), Cancer, Stress, Anesthesia, and Immune Response(20)

Publications130 total

The ITCC-P4 PDX platform of pediatric cancers for preclinical testing
2026Open Access
Supplementary Materials from First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
2025Open Access
Supplementary Materials from First-in-Human Study of AZD5153, A Small Molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
2024Open Access
Data from First-in-Human Study of AZD5153, A Small Molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
2024Open Access
Supplementary Materials from First-in-Human Study of AZD5153, A Small Molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
2024Open Access
PRIMROSE: A modular phase 1/2a study of AZD3470, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP deficient advanced solid tumors.
Journal of Clinical Oncology·2024· 9 cited
Abstract 5469: ITCC-P4, a preclinical proof-of-concept drug testing platform as a tool for pharmacological screening in pediatric tumor models
Cancer Research·2024
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer
Cancer Immunology Immunotherapy·2024· 11 citedOpen Access
Supplementary Materials from First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
2023Open Access
Data from First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
2023Open Access
Data from First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
2023Open Access
Supplementary Materials from First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
2023Open Access
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
Molecular Cancer Therapeutics·2023· 24 citedOpen Access
BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5
Blood Advances·2023· 8 citedOpen Access
Abstract 3571: The ITCC-P4 sustainable platform of fully characterized PDXs supports the preclinical proof-of-concept drug testing of high-risk pediatric tumor models
Cancer Research·2023· 4 cited
Abstract 234: ITCC-P4: Genomic profiling and analyses of pediatric patient tumor and patient-derived xenograft (PDX) models for high throughput <i>in vivo</i> testing
Cancer Research·2023· 1 cited
Supplementary Figures 1-5 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
2023Open Access
Table S1-S3; Figure S1-S13 from BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in &lt;i&gt;Kras&lt;/i&gt;-Mutant Non–Small Cell Lung Cancer
2023Open Access
Supplementary Table 1 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
2023Open Access
Supplementary Table 3 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Huawei Chen(13), Stephen E. Fawell(11), Edwin Clark(11), Janet L. Karlix(11), Gayle P. Pouliot(10), Corinne Reimer(9), Michael Zinda(9), Todd M. Bauer(9), Susanna V. Ulahannan(9), Ganesh Moorthy(9), Manish R. Patel(9), Austin Dulak(8), Gordon B. Mills(7), Shenghua Wen(7), Paul D. Lyne(7), Emerson A. Lim(7), Gerald S. Falchook(7), Deanna L. Russell(7), Rakesh Kumar(7), Garrett W. Rhyasen(6)